| Literature DB >> 15173897 |
Pierre Blier1, Gabriella Gobbi, Nasser Haddjeri, Luca Santarelli, Gina Mathew, René Hen.
Abstract
Substance P (neurokinin-1 [NK1]) receptor antagonists appear to be effective antidepressant and anxiolytic agents, as indicated in 3 double-blind clinical trials. In laboratory animals, they promptly attenuate the responsiveness of serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE) neurons to agonists of their cell-body autoreceptors, as is the case for some antidepressant drugs that are currently in clinical use. Long-term, but not subacute, antagonism of NK1 receptors in rats increases 5-HT transmission in the hippocampus, a property common to all antidepressant treatments tested thus far. This enhancement seems to be mediated by a time-dependent increase in the firing rate of 5-HT neurons. Mice with the NK1 receptor deleted from their genetic code also have an increased firing rate of 5-HT neurons. Taken together, these observations strongly suggest that NK1 antagonists could become a new class of antidepressant and anxiolytic agents.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15173897 PMCID: PMC400690
Source DB: PubMed Journal: J Psychiatry Neurosci ISSN: 1180-4882 Impact factor: 6.186